Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects
- PMID: 30081468
- PMCID: PMC6115805
- DOI: 10.3390/nu10081011
Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects
Abstract
Obesity is a risk factor for hypertension, diabetes mellitus (DM), dyslipidemia, and hyperuricemia. Here, we evaluated whether the same body mass index (BMI) for the U.S. population conferred similar metabolic risk in Japan. This was a cross-sectional analysis involving 90,047 Japanese adults (18⁻85 years) from St. Luke's International Hospital, Tokyo, Japan and 14,734 adults from National Health and Nutrition Examination Survey (NHANES) collected in the U.S. We compared the prevalence of hypertension, DM, dyslipidemia, and hyperuricemia according to BMI in Japan and the U.S. The prevalence of hypertension, DM, and dyslipidemia were significantly higher in the U.S. than Japan, whereas the prevalence of hyperuricemia did not differ between countries. Higher BMI was an independent risk factor for hypertension, DM, dyslipidemia, and hyperuricemia both in Japan and in the U.S. after adjusting for age, sex, smoking and drinking habits, chronic kidney disease, and other cardiovascular risk factors. The BMI cut-off above which the prevalence of these cardio-metabolic risk factors increased was significantly higher in the U.S. than in Japan (27 vs. 23 kg/m² for hypertension, 29 vs. 23 kg/m² for DM, 26 vs. 22 kg/m² for dyslipidemia, and 27 vs. 23 kg/m² for hyperuricemia). Higher BMI is associated with an increased prevalence of hypertension, DM, dyslipidemia, and hyperuricemia both in Japan and U.S. The BMI cut-off above which the prevalence of cardio-metabolic risk factors increases is significantly lower in Japan than the U.S., suggesting that the same definition of overweight/obesity may not be similarly applicable in both countries.
Keywords: body mass index; epidemiology; hypertension; risk factor.
Conflict of interest statement
Johnson has equity with XORT Therapeutics, which is developing novel xanthine oxidase inhibitors, and with Colorado Research Partners LLC which is developing inhibitors of fructose metabolism. In addition, Johnson is an inventor on several patents licensed to XORT Therapeutics. (U.S. Patent No 7,799,794, U.S. Patent No. 8,557,831). The other authors have nothing to disclose.
Figures
References
-
- Chen Y., Copeland W.K., Vedanthan R., Grant E., Lee J.E., Gu D., Gupta P.C., Ramadas K., Inoue M., Tsugane S., et al. Association between body mass index and cardiovascular disease mortality in east asians and south asians: Pooled analysis of prospective data from the asia cohort consortium. BMJ. 2013;347:f5446. doi: 10.1136/bmj.f5446. - DOI - PMC - PubMed
-
- WHO Global Health Observatory (GHO) Data; Overweight and Obesity. [(accessed on 2 August 2018)]; Available online: http://www.who.int/gho/ncd/risk_factors/overweight/en/
-
- Senauer B., Gemma M. Why is the Obesity Rate So Low in Japan and High in the U.S.? Some Possible Economic Explanations. [(accessed on 2 August 2018)];Food Ind. Center Univ. Minn. 2006 Available online: http://ageconsearch.umn.edu/record/14321/files/tr06-02s.pdf?version=1.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
